ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Expands Indication for PROGRAF? for Lung Transplant Recipients americanpharmaceuticalreview
July 22, 2021Astellas Pharma Inc. announced that the U.S. FDA approved its supplemental New Drug Application (sNDA) for PROGRAF? (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients. -
Elevated Risk for Lung CA in Lung Transplant Recipients Explored
drugs
December 28, 2018Recipients of a lung transplant, especially a single lung transplant, have an elevated risk for lung cancer, particularly in the native lung, according to a study published online Dec. 18 in the?American Journal of Transplantation......
Pharma Sources Insight January 2025
